Tandamine (AY-23,946)- a new norepinephrine reuptake inhibitor with practically no serotonin potentiation, MAO inhibition and anticholinergic activity-was administered in doses from 75 to 200 mg to a group of 20 hospitalized depressed patients. Weekly clinical evaluation including the ECDEU global score. Hamilton score and Zung self-rating score demonstrated a slight improvement which became statistically significant between the 1st and 2nd weeks of therapy. While the 'thymoleptic' properties of the drug were weak, a pronouned 'activating/stimulatory' effect of the drug was noted. Psychometric tests showed an increase in attention, concentration and psychomotor activity as well as an improvement in FPI personality dimensions 'depression' and 'inhibition', while the Taylor anxiety score did not reveal any changes. Digital computer period analysis of the EEG demonstrated, 6 h after oral administration of 50 mg tandamine, a decrease of slow waves, a significant increase of fast activity as well as a significant attenuation of the amplitude variability. Such changes are reminiscent of the pharmaco-EEG profile of psychostimulatory drugs and may represent the neurophysiological correlate for the activating/stimulatory properties of tandamine. Our finding suggest that the well-tolerated drug may be of some benefit for retarded depressions.

01 Jan 1977·Experientia

Effects of 1-alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines and related compounds, potential antidepressants, on biogenic amine uptake mechanisms

Article

Author: W. Lippmann ; T. A. Pugsley

A new series of compounds structurally related to the potential antidepressant tandamine, i.e., the 1-alkyl-1,2,3,4-tetrahydrocarbazole-1-ethanamines, inhibit the noradrenaline uptake mechanism and are relatively ineffective in inhibiting the serotonin uptake mechanism in vivo. The potency of the most effective compound (9-ethyl-N,N,1-trimethyl-1,2,3,4-tetrahydrocarbazole) is similar to that of desimipramine and is of potential use in the treatment of endogenously depressed patients.

100 Deals associated with Tandamine

External Link

KEGG	Wiki	ATC	Drug Bank
-	Tandamine	-	DB09192

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder	Preclinical	US	Ayerst Laboratories, Inc.	05 May 1976

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis